東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy./
作者:	Linde, Miles Hamilton.
面頁冊數:	1 online resource (72 pages)
附註:	Source: Dissertations Abstracts International, Volume: 84-04, Section: B.
Contained By:	Dissertations Abstracts International84-04B.
標題:	Cytokines. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29342299click for full text (PQDT)
ISBN:	9798351496498

Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy.
Linde, Miles Hamilton.

Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy. - 1 online resource (72 pages)

Source: Dissertations Abstracts International, Volume: 84-04, Section: B.

Thesis (Ph.D.)--Stanford University, 2022.

Includes bibliographical references

Therapeutic cancer vaccination seeks to elicit activation of tumor-reactive T cells capable of recognizing tumor-associated antigens (TAAs) and eradicating malignant cells. Here, we present a cancer vaccination approach utilizing myeloid lineage reprogramming to directly convert cancer cells into tumor reprogrammed-APCs (TR-APCs). Using syngeneic murine leukemia models, we demonstrate that TR-APCs acquire both myeloid phenotype and function, process and present endogenous TAAs, and potently stimulate TAA-specific CD4+ and CD8+ T cells. In vivo TR-APC induction elicits clonal expansion of cancer-specific T cells, establishes cancer-specific immune memory, and ultimately promotes leukemia eradication. We further show that both hematologic cancers and solid tumors, including sarcomas and carcinomas, are amenable to myeloid-lineage reprogramming into TR-APCs. Finally, we demonstrate the clinical applicability of this approach by generating TR-APCs from primary clinical specimens and stimulating autologous patient-derived T cells. Thus, TR-APCs represent a cancer vaccination therapeutic strategy with broad implications for clinical immuno-oncology.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2023

Mode of access: World Wide Web

ISBN: 9798351496498Subjects--Topical Terms:

687114
Cytokines.
Index Terms--Genre/Form:

542853
Electronic books.

Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy.
LDR:02505nmm a2200385K 4500 001 2359823
005 20230917195257.5
006 m o d
007 cr mn ---uuuuu
008 241011s2022 xx obm 000 0 eng d
020 $a 9798351496498
035 $a (MiAaPQ)AAI29342299
035 $a (MiAaPQ)STANFORDhd601vf0379
035 $a AAI29342299
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Linde, Miles Hamilton. $3 3700437
245 1 0 $a Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy.
264 0 $c 2022
300 $a 1 online resource (72 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 84-04, Section: B.
500 $a Advisor: Bendall, Sean; Engleman, Edgar G; Levy, Ronald.
502 $a Thesis (Ph.D.)--Stanford University, 2022.
504 $a Includes bibliographical references
520 $a Therapeutic cancer vaccination seeks to elicit activation of tumor-reactive T cells capable of recognizing tumor-associated antigens (TAAs) and eradicating malignant cells. Here, we present a cancer vaccination approach utilizing myeloid lineage reprogramming to directly convert cancer cells into tumor reprogrammed-APCs (TR-APCs). Using syngeneic murine leukemia models, we demonstrate that TR-APCs acquire both myeloid phenotype and function, process and present endogenous TAAs, and potently stimulate TAA-specific CD4+ and CD8+ T cells. In vivo TR-APC induction elicits clonal expansion of cancer-specific T cells, establishes cancer-specific immune memory, and ultimately promotes leukemia eradication. We further show that both hematologic cancers and solid tumors, including sarcomas and carcinomas, are amenable to myeloid-lineage reprogramming into TR-APCs. Finally, we demonstrate the clinical applicability of this approach by generating TR-APCs from primary clinical specimens and stimulating autologous patient-derived T cells. Thus, TR-APCs represent a cancer vaccination therapeutic strategy with broad implications for clinical immuno-oncology.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2023
538 $a Mode of access: World Wide Web
650 4 $a Cytokines. $3 687114
650 4 $a Immunology. $3 611031
650 4 $a Lymphocytes. $3 895384
650 4 $a E coli. $3 3556834
650 4 $a Bone marrow. $3 1621080
650 4 $a Tumors. $3 893964
650 4 $a Spinal cord. $3 895443
650 4 $a Cell growth. $3 3560747
650 4 $a Immunocompetence. $3 3700438
650 4 $a Morphology. $3 591167
650 4 $a Transcription factors. $3 669191
650 4 $a Biology. $3 522710
650 4 $a Cellular biology. $3 3172791
650 4 $a Medicine. $3 641104
650 4 $a Oncology. $3 751006
650 4 $a Cancer. $3 634186
650 4 $a Vaccines. $3 684854
650 4 $a Chemokines. $3 702040
650 4 $a Antigen presentation. $3 3564522
650 4 $a Fibroblasts. $3 1573241
650 4 $a Leukemia. $3 677274
650 4 $a Mortality. $3 533218
655 7 $a Electronic books. $2 lcsh $3 542853
690 $a 0287
690 $a 0982
690 $a 0306
690 $a 0379
690 $a 0564
690 $a 0992
710 2 $a ProQuest Information and Learning Co. $3 783688
710 2 $a Stanford University. $3 754827
773 0 $t Dissertations Abstracts International $g 84-04B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29342299 $z click for full text (PQDT)